Randomised controlled pilot study to investigate the effectiveness of thoracic epidural and paravertebral blockade in reducing chronic post-thoracotomy pain: TOPIC feasibility study protocol. by Yeung, Joyce et al.
Randomised controlled pilot study to
investigate the effectiveness of thoracic
epidural and paravertebral blockade in
reducing chronic post-thoracotomy pain:
TOPIC feasibility study protocol
Joyce Yeung,1,2 Teresa Melody,2 Amy Kerr,3 Babu Naidu,1,3 Lee Middleton,4
Kostas Tryposkiadis,4 Jane Daniels,4 Fang Gao,1,2 on behalf of the TOPIC Study
Investigators
To cite: Yeung J, Melody T,
Kerr A, et al. Randomised
controlled pilot study to
investigate the effectiveness
of thoracic epidural and
paravertebral blockade in
reducing chronic post-
thoracotomy pain: TOPIC
feasibility study protocol.
BMJ Open 2016;6:e012735.
doi:10.1136/bmjopen-2016-
012735
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2016-
012735).
Received 23 May 2016
Revised 31 October 2016
Accepted 10 November 2016
For numbered affiliations see
end of article.
Correspondence to
Professor Fang Gao;
f.gaosmith@bham.ac.uk
ABSTRACT
Introduction: Open chest surgery (thoracotomy) is
considered the most painful of surgical procedures.
Forceful wound retraction, costochondral dislocation,
posterior costovertebral ligament disruption, intercostal
nerve trauma and wound movement during respiration
combine to produce an acute, severe postoperative
pain insult and persistent chronic pain many months
after surgery is common. Three recent systematic
reviews conclude that unilateral continuous
paravertebral blockade (PVB) provides analgesia at
least equivalent to thoracic epidural blockade (TEB) in
the postoperative period, has a lower failure rate, and
symptom relief that lasted months. Crucially, PVB may
reduce the development of subsequent chronic pain by
intercostal nerve protection or decreased nociceptive
input. The overall aim is to determine in patients who
undergo thoracotomy whether perioperative PVB
results in reducing chronic post-thoracotomy pain
(CPTP) compared with TEB. This pilot study will
evaluate feasibility of a substantive trial.
Methods and analysis: TOPIC is a randomised
controlled trial comparing the effectiveness of TEB
and PVB in reducing CPTP. This is a pilot study to
evaluate feasibility of a substantive trial and study
processes in 2 adult thoracic centres, Heart of
England NHS Foundation Trust (HEFT) and University
Hospital of South Manchester NHS Foundation Trust
(UHSM). The primary objective is to establish the
number of patients randomised as a proportion of
those eligible. Secondary objectives include evaluation
of study processes. Analyses of feasibility and
patient-reported outcomes will primarily take the form
of simple descriptive statistics and where appropriate,
point estimates of effects sizes and associated
95% CIs.
Ethics and dissemination: The study has obtained
ethical approval from NHS Research Ethics Committee
(REC number 14/EM/1280). Dissemination plan
includes: informing patients and health professionals;
engaging multidisciplinary professionals to support a
proposal of a definitive trial and submission for a full
HTA application dependent on the success of
the study.
Trial registration number: ISRCTN45041624; Pre-
results.
INTRODUCTION
Open chest surgery (thoracotomy) is consid-
ered the most painful of surgical procedures.1
Forceful wound retraction, costochondral
dislocation, posterior costovetebral ligament
disruption, direct intercostal nerve trauma
and wound movement during respiration
combine to produce an acute, severe
Strengths and limitations of this study
▪ Chronic pain post-thoracotomy is common and
can result in significant economic and healthcare
burden. Very little is known about whether
anaesthetic and analgesic technique will prevent
chronic pain.
▪ This randomised controlled pilot study will
assess patient recruitment to a definitive study.
▪ Results from this study will contribute towards
limited evidence towards prevention of develop-
ment of chronic post-thoracotomy pain.
▪ This pilot study will not answer the research
question but will lead to well-designed definitive
study.
▪ To maintain patient safety and clinical care, post-
operative clinical teams looking after patients are
not blinded to anaesthetic technique patient has
received. The low risk of patients knowing their
treatment allocation can potentially introduce
bias. To limit bias, the outcome assessors are
blinded to anaesthetic techniques and patients
were not informed of treatment allocation.
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postoperative pain insult and persistent chronic pain
many months after surgery is common.1–5 Chronic post-
thoracotomy pain (CPTP) is deﬁned by the International
Association for the Study of Pain, as pain that recurs or
persists along a thoracotomy incision at least 2 months
following the surgical procedure.6 The aetiology of CPTP
seems to be nociceptive and neuropathic in nature. Risk
factors include female gender, younger age, psycho-
logical vulnerability and intercostal nerve damage.7 8
CPTP can be very disabling and results in a substantial
economic and healthcare burden. About 8500 surgical
lung resections are performed annually in the UK
mainly for lung cancer.9 Our literature review suggests
that CPTP occurs in 43% of patients, who had no pre-
existing pain problem, at 6 months after surgery. Other
surveys indicate 66% of patients suffered from pain that
impaired normal daily activity for at least 12 months after
thoracotomy, 90% of affected patients required prescrip-
tion medications for pain and anxiety while 30%
received specialist treatments.10 About 29% of patients
with CPTP have neuropathic pain that is harder to treat
than somatic pain. Of these, 43% experienced some
level of disruption in their employment status, including
reduced working time, unemployment or early
retirement.11 12
Current practice
Thoracic epidural blockade (TEB) is currently regarded
as the ‘gold standard’ for pain relief in thoracotomy;
however, this dogma has recently been challenged.
Recent evidence from two meta-analyses and systematic
reviews comparing the analgesic efﬁcacy and side effects
of epidural versus paravertebral blockade (PVB) for
thoracotomy pain control concluded that although the
analgesia was comparable, PVB had a better short-term
side effect proﬁle, including urinary retention, hypoten-
sion, nausea and vomiting and pulmonary
complications.13 14
Despite the evidence, previous surveys of clinical prac-
tice have consistently demonstrated that thoracic epi-
dural remained the most popular choice. A survey of
Australian thoracic anaesthetists in 1997 revealed that
79% regarded TEB as the method of choice for anal-
gesia in thoracotomy.15 Similar results were found in the
UK with 80% of anaesthetists considered TEB as the
best mode of pain relief for upper abdominal surgery.16
A 2011 survey of 39 thoracic units in the UK that was
carried out by the Association of Cardiothoracic
Anaesthetists (ACTA) reported that the majority of thor-
acic anaesthetists (2/3 units) prefer TEB to PVB, which
suggests that most thoracic anaesthetists have yet to be
convinced by the evidence available.17
Effect of anaesthesia and analgesic technique
The physiological response to surgically induced tissue
injury is analogous to an acute systemic inﬂammatory
response. This is pertinent to thoracotomy, during which
musculoskeletal disruption from retraction, intercostal
nerve injury and pleural breach is impossible to avoid
even with meticulous surgical technique. It is almost
certain that the interaction of these factors results in the
high prevalence of CPTP.8 18 19 The somatic afferent
neuronal trafﬁc generated by surgery is integrated at
spinal cord level before onward transmission to the
higher central nervous system. Elaboration of this input
via the thalamus and onward to the cerebral cortex
results in the sensation of localised acute pain and the
psychological and emotional responses of distress. This
afferent information can be modulated by therapeutic
nerve blockade or a reduction in its humoral conse-
quences, for example, by the addition of anti-
inﬂammatory agents. Nerve block reduces acute symp-
toms by preventing pain transmission. It may also reduce
the complex ‘elaboration’ of pain pathways at a spinal
cord level and thus desensitise pathways that underpin
the development of chronic pain. Preventing this sensi-
tisation is proposed as the basis for the so-called
‘Pre-emptive analgesia’.11 If spinal cord sensitisation
does play a role in CPTP, it follows that the less excita-
tory information transmitted to spinal cord level, the
greater the chance of chronic pain prevention.
Although TEB and PVB use local anaesthetics to reduce
afferent input, their sites of action are different. TEB is
a central neuraxial blockade, effective at spinal cord
level bilaterally. It does not induce complete neural
‘Silence’ but reduces onward transmission by a combin-
ation of local anaesthetic-induced sodium channel
blockade and opioid interaction in the substantial gelati-
nosa. In contrast, the effect of PVB is dependent on
local anaesthetic-mediated prevention of peripheral
nociceptive afferent trafﬁc reaching the spinal cord.20 21
In this sense, quiescence of this neuronal input may be
more complete with an effective PVB. There is therefore
a sound theoretical basis to hypothesise divergent effects
of the two techniques on cord sensitisation and subse-
quent CPTP generation.
The evidence for the comparative effectiveness of PVB
and TEB
Three recent systematic reviews conclude that unilateral
continuous PVB provides analgesia at least equivalent to
TEB in the postoperative period, has a lower failure rate,
and symptom relief that lasted months.13 14 PVB resulted
in fewer pulmonary complications, less urinary reten-
tion, hypotension and nausea/vomiting.22 In 2005, in a
multicentre UK audit of 365 pneumonectomies, PVB
was associated with signiﬁcantly lower major post-
operative complications (23% vs 35%) and lower unex-
pected intensive care unit admissions (8% vs 18%)
compared with TEB.23 The beneﬁts seen with PVB can
be explained by the blocking of unilateral intercostals
nerves only, with preservation of respiratory and sympa-
thetic function on the contralateral side. These reviews
were updated in October 2012 with six additional trials,
ﬁve of which20 22–25 (total n=244) supported the conclu-
sions of the systematic reviews; however, a small trial
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found the median morphine consumption signiﬁcantly
higher with PVB (n=12) than the TEB group (n=12) (9
vs 36 mg, p=0.003).20 Crucially, PVB may reduce the
development of subsequent chronic pain by intercostal
nerve protection or decreased nociceptive input.21
Previous trials directly comparing TEB and PVB have
not examined chronic pain as the primary outcome
and as a result, evidence that PVB is superior in pre-
venting CPTP is derived from other sources. PVB has
long been used as a treatment (rather than prevention)
of CPTP to good effect, with symptom relief lasting
months. Observational studies have reported lower
chronic pain rates after PVB relative to TEB, albeit with
non-randomised methodology. Local anaesthetic-
induced PVB has been proven to abolish cortical som-
atosensory-evoked potentials from thoracic dermatome
stimulation.21 There is no evidence for an equivalent
abolition in TEB. Prevention of afferent input to the
central nervous system is known to be important in
pain modulation. Total blockade of somatosensory-
evoked potentials by PVB removes the stimulus for
central sensitisation and could be uniquely effective in
preventing CPTP from being triggered. There are many
parallels between CPTP and chronic pain after breast
surgery with recent trial evidence suggesting that
PVB exerts a beneﬁcial effect in chronic pain
prevention.20 26
The most recent Cochrane Review comparing PVB
and TEB in adults undergoing thoracotomy found no
difference between PVB and TEB in 30-day mortality fol-
lowing surgery.27 PVB was associated with a lower inci-
dence of pneumonia and delirium when compared with
TEB. No signiﬁcant difference between PVB and TEB
was found in critical care admission and there were
insufﬁcient data to compare the two techniques in terms
of cardiovascular complications or the need for further
surgery. In terms of analgesic efﬁcacy, PVB was compar-
able to TEB and was found to be superior at 24 hours
postoperatively. PVB also had a better minor complica-
tion proﬁle with lower incidence of hypotension, nausea
and vomiting, pruritus and urinary retention. No differ-
ence between PVB and TEB was found in excessive sed-
ation and length of hospital stay. There were insufﬁcient
data to compare PVB and TEB in terms of assessing
CPTP and health costs.
The review also concluded that a well-conducted ran-
domised controlled trial (RCT) comparing PVB and
TEB in thoracotomy is needed. Areas that require
further research include 30-day mortality, major compli-
cations, chronic pain and health costs.
Study rationale
CPTP is unpleasant and disabling. Surveys have indi-
cated 66% of patients suffered pain that impaired their
normal daily activity for at least 12 months after
thoracotomy.10 Ninety per cent of affected patients
required prescription medications for pain and anxiety.
Of these, 43% experienced disruption in their
employment status. CPTP certainly results in substantial
economic and healthcare burden. It is expected that the
number of patients suffering CPTP will increase follow-
ing the rise in number of lung resections over the last
decade (around 60%) in the UK and Ireland. There is
now an urgent need to answer this important research
question for beneﬁts to patients and the NHS.
If one technique proves to be signiﬁcantly better, our
results will inﬂuence national policy and directly
improve patient care. Our results will also be applicable
to the prevention of chronic postsurgical pain from
other one side operations, such as hernia repair, leg
amputation, gallbladder removal or breast surgery.
Study aim
The overall aim of this research is to determine in adult
patients who undergo open chest operation whether
perioperative PVB at thoracotomy results in reducing
CPTP compared with TEB. To answer this research ques-
tion with authoritative evidence of clinical and cost-
effectiveness of PVB, a multicentre RCT with a parallel
health economic evaluation is required.
However, feasibility studies are the best way to assess
feasibility of a large, expensive full-scale study, and in
fact are an almost essential prerequisite. Conducting
feasibility prior to the main study can enhance the likeli-
hood of success of the main study and potentially help
to avoid doomed main studies.28 We have therefore
designed this multicentre feasibility study comparing the
effectiveness of TEB and PVB in reducing CPTP. This
study will evaluate feasibility of a substantive trial and
study processes by making the following qualitative and
quantitative assessments.
Objectives for the feasibility study
The aims of the feasibility stage are to assess various
aspects of the trial design and management and not to
determine the relative effectiveness of PVB and TEB.
Primary objective
To establish the number of patients randomised as a
proportion of those eligible to enter the study.
Secondary objectives
1. Assessment of effectiveness of patient identiﬁcation
and screening processes
2. Identiﬁcation and analysis of any reasons for failure
to recruit patients
3. Examination of the educational materials provided
to surgeons and anaesthetists to ensure they are ﬁt
for purpose
4. Assessment of willingness of surgeons and anaesthe-
tists to participate
5. Assessment of the effectiveness of the randomisation
process of patients
6. Assessment of sustainability of single blinding of
patients to treatment allocation
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7. Evaluation of robustness of data collection processes
during patient’s hospital stay
8. The proportion of patients followed up at 6 months
9. Acceptability to and impact on patients of the
interventions
10. Assessment of trial processes, including the choice
of outcome measures and impact on staff
11. Derivation of the preliminary data from clinical
outcome measures to inform the sample size calcu-
lation for the substantive study
TRIAL DESIGN
Design
TOPIC is an RCT comparing the effectiveness of TEB
and PVB in reducing CPTP. This is a pilot study to
evaluate feasibility of a substantive trial and study
processes.
Setting
The study started in July 2015 with ﬁnal follow-up to end
December 2016. Two adult thoracic centres, Heart of
England NHS Foundation Trust (HEFT) and University
Hospital of South Manchester NHS Foundation Trust
(UHSM), with a patient case mix and size typical of UK
thoracic anaesthetic practice, will take part in this feasi-
bility. Based on National Thoracic Surgery Activity and
Outcome Report and local audit data, an estimated total
of 500 elective open thoracotomies were performed at
BHH (n=400) and at UHSM (n=100) in 2011. All adult
patients admitted for elective thoracotomy who fulﬁl the
inclusion and exclusion criteria during the study period
will be approached at both sites. The coordinating
centre will be based within MIDRU in Birmingham
Heartlands Hospital.
Flow of participants during the trial
The anticipated journey of participants through the trial
is depicted in the ﬂow chart as indicated in ﬁgure 1.
All adults undergoing planned elective thoracotomy at
study sites fulﬁlling inclusion and exclusion criteria will
be approached and the trial written information sheets
will be given to them and the study will be discussed
fully. Written informed consent will be obtained.
Patients who consent to participate in the trial will be
randomised to either receiving the TEB or PVB arm
which will be delivered during the patient’s surgery by
either a surgeon or an anaesthetist trained in the study
protocol. Patients will be randomised on the morning of
the surgery. If either the surgeon or anaesthetist is not
available to deliver the intervention, randomisation will
not go ahead.
Presurgery and postsurgery study data collection will
be performed and study questionnaires will be com-
pleted, as detailed. Adverse events will be collected
throughout the duration of patients’ participation in the
study. Table 1 is a summary of investigations and
assessment.
Study eligibility
Inclusion criteria
▸ Aged ≥18 years
▸ Elective open thoracotomy
▸ Able to understand the study information and
provide written informed consent
▸ American Society of Anaesthesiologists physical status
I, II or III
▸ Not known to be pregnant
Exclusion criteria
▸ Known allergy to local anaesthetics
▸ Infection near the proposed puncture site
▸ Coagulation disorders
▸ Thoracic spine disorders
▸ Chest wall resection
▸ Emergency thoracic surgery
▸ Previous thoracotomy
▸ Likely inability to comply with completion of the
study questionnaires
Patient identification and screening procedure
Research staff will work in close liaison with the multidis-
ciplinary team responsible for routine patient care.
Patients listed for elective open thoracotomy will be
identiﬁed and screened for eligibility at clinics prior to
their planned surgery. If a patient is screened but is not
eligible for the TOPIC trial or consent for randomisa-
tion is not given, a record of the case will be kept in the
screening log. The log will collect hospital number,
patient’s initials, date of birth, age, ethnic group, BMI
and reason not eligible for the trial. The log should be
kept in each study centre’s site ﬁle and a copy (in an
anonymised format—removing initials and hospital
number) sent to TOPIC trial ofﬁce. This will inform
recruitment targets. No further information will be col-
lected on ineligible patients or those that have not given
consent for randomisation.
Patient recruitment
Ideally, consent should be sought under unhurried circum-
stances when entry criteria are fulﬁlled. Consent is sought
in several stages. We aim to identify patients who will need
a planned surgical thoracic operation within the two
recruiting study sites. Eligible patients will be identiﬁed in
clinics prior to surgery. Ethically approved participant
information sheet will be given to eligible patients, sup-
ported by face-to-face discussion with the research team
and their consultant. The participant information sheet
has been developed with feedback from our PPI represen-
tatives, and any ambiguities, or questions frequently asked
by those approached, will be collated. This will enable a
comprehensive, but clear, participant information sheet to
be deployed if we proceed onto a substantive trial.
If patient consents to participate in the study, written
informed consent will be obtained by a member of the
research team. Enough time will be given to discuss the
study, ask any questions before seeking consent. If the
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patient decides to enter the trial, they will be asked to
sign two original copies of the patient consent form
which will then be countersigned by the member of the
research team taking the consent. The patient will retain
one copy of the signed consent form. The second copy
will be photocopied and the photocopy placed in the
patient’s medical records while the original will be
retained in the Investigator Site File.
Participants will be asked to consent to their GP being
informed about their participation in the study.
Randomisation
After written informed consent, the patient will be ran-
domised, on the day of surgery, to either TEB or PVB.
Participants will be individually randomised into the
study in an equal 1:1 ratio. Randomisation will be by a
web-based randomisation system, with a telephone
option available as back-up, managed by the
Birmingham Clinical Trials Unit (BCTU).
A ‘minimisation’ procedure using a computer-based
algorithm and incorporating a random element will be
used to avoid chance imbalances in the following vari-
ables. The variables chosen are:
▸ gender,
▸ age <65 or ≥65 years,
▸ centre (Birmingham Heartlands Hospital or
University Hospital of South Manchester),
Figure 1 Flow of participants during the trial.
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▸ thoracotomy for lung cancer resection or for other
indication.
Using the web-based randomisation service, patients
will be allocated to a treatment group. The anaesthetist
and surgeon in charge of patient care will be informed
of the patient’s allocation. A unique study identiﬁcation
number will be assigned to the participant.
Study anaesthetic and analgesic strategies
All study patients will be anaesthetised by experienced
thoracic anaesthetists (consultants) who have been
trained and deemed competent in both anaesthetic tech-
niques. The study team has worked closely with consult-
ant anaesthetists to develop a suitable training package.
Consultant anaesthetists are capable to perform epidur-
als and PVBs; however, for the purpose of the study,
anaesthetists will be asked to perform the techniques to
the standard required by study protocol. Two online
training videos detailing TEB and PVB have been pro-
duced alongside supplementary written step-by-step
guide. A copy of the videos is also available in DVD
format. All anaesthetists participating in the study must
review video and/or written material and conﬁrm that
they are able to perform the techniques according to
study protocol. Further training, if required, will be pro-
vided by study-designated trainers at each participating
sites who can demonstrate and observe performance if
required. All training material will be freely available at
each site and will act as a reference for participating
anaesthetists and surgeons. Training by participating
anaesthetists will be documented in training logs.
To be pragmatic, some variation in technical aspects
of block insertion detailed in the training is anticipated,
between experienced thoracic anaesthetists, and those
trained for the trial, and between centres, as anaesthe-
tists will use their judgement on the best techniques for
each patient. This represents real-world variation in
anaesthetic practices and will not contribute to bias
since randomisation will ensure balance across groups
by centre. The location and dose of anaesthetic will be
captured on a postoperative case report form (CRF).
Experimental group: PVB
Three single injections, awake or asleep, using a 16 G/
18 G graduated epidural needle with 15 mL 0.25% bupi-
vacaine at T3–4, 5–6 and 7–8, will be given preopera-
tively. The PVB catheter will be placed at T5 under
direct vision by a surgeon at the end of surgery before
chest closure. A loading dose of 10 mL 0.25% bupiva-
caine is given before chest closure followed by infusion
of 0.125% bupivacaine 0.1–0.25 mL/kg/hour. See
online supplementary appendix for further details.
Table 1 Summary of investigations and assessments
Baseline clinic
appointment prior
to surgery
In-hospital Follow-up
Intraoperative
Day
one*
Day
two*
Day
three*
Hospital
discharge
Three
months
Six
months
Eligibility and written
informed consent†
X
Demographic data X
Previous Medical History X
Randomisation X
Day of surgery
TEB/PVB insertion data X
Other intraoperative data X
Post operative observations X X X X
Post-operative pulmonary
complications
X X X X
Visual Analogue Scale score X X X X X X X
Brief Pain Inventory X X X X X X X
Post-operative analgesic use X X X X X X
Acute Complications X X X X
Hospital Length of Stay X
Mortality If applicable
Neuropathic Pain Scale X X X X
Discharge data and histology
data
X
EQ-5D-5L X X X X
Hospital Anxiety Depression
Scale
X X X X
Patient satisfaction X X X
Adverse Events If applicable
Protocol deviations If applicable
*Day 1 is the first full calendar (from 12 midnight) postsurgery, day 2 is the second full calendar day, day 3 is the third full calendar day.
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Control group: TEB
Usual practice of TEB, awake or asleep, using a 16 G/18
G graduated epidural needle with a catheter inserted at
the spinal level supplying the skin at the incision site, a
test dose of 3 mL of 0.25% bupivacaine, and a loading
dose of 0.25% bupivacaine 0.1 mL/kg with up to 3 mg
of diamorphine. This will be followed by infusion of
0.125% bupivacaine with 2 μg/mL fentanyl at 0.1–
0.25 mL/kg/hour. See online supplementary appendix
for further details.
Study treatment dispensing
All anaesthetics and analgesia will be taken from stand-
ard theatre pharmacy stock. As TOPIC does not fall
under the Medicines for Human Use (Clinical Trials)
regulations 2004, segregated stocks for trial use and spe-
ciﬁc trial labelling are not required. Temperature moni-
toring should follow local pharmacy practice and
deviations need not be reported to the TOPIC Study
Co-ordinator.
Blinding of trial allocations
By the nature of the interventions, it is not possible to
conceal treatment assignments from surgeons and
anaesthetists. Moreover, from a safety aspect, it is vital
that the nursing staff caring for the patient know the
amount of epidural opiates prescribed before adminis-
tering systemic opiates, and known adverse events such
as hypotension or pruritus expected to arise from the
respective anaesthetic approaches.
Every attempt will be made to blind study participants
to their group allocation. The epidural or PVB infusion
catheter will be taped laterally on the side of operation,
so no visible difference can be seen by the patient.
Infusion pumps used by both groups will also be
identical.
Withdrawal from the trial
Withdrawal from the trial before surgery is a decision of
the participant; however, withdrawn patients can bias
trial results and reduce the power of the trial to detect
important differences, so randomisation will take place
as close to the time of surgery as is practical in order to
reduce postrandomisation withdrawals. Following
surgery, participants should be encouraged to allow clin-
ical data collection to continue even if they decline to
complete further questionnaires.
Cessation of the allocated anaesthetic strategy will also
be necessitated in cases where a known serious adverse
reaction to the anaesthetic occurs or a suspected unex-
pected serious adverse reaction occurs.
Protocol violations
Any incidences of study participants not receiving the
anaesthetic strategy allocation by randomisation will be
recorded. All study and protocol violations and devia-
tions will be documented in the patients CRF and
reported to the Study Sponsor via the Trial Ofﬁce.
Patients will be analysed according to group allocation,
by intent-to-treat analysis.
Additional intraoperative analgesia
Supplementary intraoperative analgesia will not be
restricted and can follow local policy. Analgesia and
doses will be recorded as part of the study in the
patients CRF.
Postoperative analgesia
Both groups should continue with TEB/PVB infusion of
0.1–0.25 mL/kg/hour bupivacaine, in the ﬁrst instance
for 48 hours postoperatively. All participants will receive
regular paracetamol and prophylactic antiemetics unless
contraindicated. Non-steroidal anti-inﬂammatory drugs
can also be administered if appropriate. All analgesic
requirements will be recorded during inpatient
follow-up.
For the TEB group, intravenous morphine boluses will
be prescribed for breakthrough pain which is not
relieved by the epidural top ups. If the epidural is inef-
fective and no block is evident, the TEB can be rein-
serted at the discretion of the anaesthetic team. If pain
relief is inadequate, morphine PCA (patient-controlled
analgesia) can be administered.
For the PVB group, intravenous morphine boluses fol-
lowed by morphine PCA will start on recovery from
anaesthesia.
OUTCOMES AND DATA COLLECTION
Patient recruitment into study
The overall aims of the feasibility are to ﬁnd out if a
larger trial is feasible. The quantitative measurements
related to this include
▸ proportion of all elective thoracic procedures
screened,
▸ proportion of eligible participants of those screened,
▸ proportion of eligible participants randomised.
In this feasibility study of two centres, HEFT and
University of south Manchester NHS Foundation Trust,
there would be an approximate total of 500 elective
open thoracotomies over the study period. The plan will
be to recruit and randomise as many patients as possible
over the 12-month study period. It is expected that
between 50 and 75 eligible patients will be recruited
from 2 sites.
Patient identification and screening
We would expect a very high proportion of patients to
be screened across both study sites, given that only
patients with planned thoracotomy will be included. The
proportion of patients screened for eligibility and
recorded on a screening log will be assessed and
reported as proportion of patients screened from the
total number of planned thoracotomies during the study
period.
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Reasons for failure to recruit
The proportion of patients that were missed, which
should be minimal, and the proportion of patients who
decline to take part will be recorded. Patients decline
for many reasons, which should be captured whenever
possible. We will consent declining patients to a short
interview. The reasons for declining will be recorded
anonymously and analysed by the research team. If
there is a strong patient preference, the substantive trial
may not be feasible, similarly if this population is disin-
terested or conversely, taking part in other trials that pre-
clude concurrent participation.
Educational materials and training of surgeons and
anaesthetists
Feedback on the appropriateness, value and acceptabil-
ity of the training will be elicited from the feasibility
sites, to enable reﬁnement of the training programme
for the substantive study, and to deﬁne a minimum
competence. The training material will be evaluated for
its ease of use should it be used in the substantive
study.
Evaluation of willingness of anaesthetists and surgeons to
participate
As part of preparation of the study site, all anaesthe-
tists and surgeons in both sites will be approached to
evaluate willingness to participate in the trial. The Site
PI(s) and the trial coordinator will discuss the proto-
col to ensure that all inclusion/exclusion criteria and
technical aspects are well understood by the participat-
ing anaesthetists and surgeons. Patient ‘vignettes’,
typical and unusual, will be presented during this
training to establish whether uncertainty exists and
therefore randomisation is ethical in all situations, or
whether there are somewhere either technique is pre-
ferred. Training material will be revised, as per the
feedback for use in the substantive study, portraying
best practice in approaching and consenting
participants.
The study team will also conduct a repeat national
survey to assess willingness from the clinical community
nationally towards the end of feasibility study.
Effectiveness of randomisation process
This would be ascertained by the speed in which
patients can be randomised and whether important
prognostic data can be collected preoperatively.
Assessment of data collection process
Assessment and identiﬁcation will be made for loss of
data during inhospital stay to improve data collection
process for the substantive trial.
Assessment of sustainability of single blinding of patients
to treatment allocation
By the nature of the interventions, it is not possible to
conceal treatment assignments from surgeons and
anaesthetists. Every attempt will be made to blind study
participants to their group allocation and various
methods may be considered. The patient-reported out-
comes will be collected remote in time from the acute
intervention. There is no reason to suspect that recipi-
ents of the randomised intervention have strong precon-
ceptions with regard to the relative effectiveness of each
analgesic technique. In this feasibility study, patients will
be asked at 3 and 6 months after surgery via question-
naire which technique they think they received to test if
our various methods for patient blinding were effective.
Assessment of follow-up rates
The primary outcome of the substantive study is chronic
pain assessed at 6-month postrandomisation. It is there-
fore vital for the appropriate measures to be in place to
minimise the loss of follow-up.
The research team will demonstrate and assist the
patient to complete the questionnaires in person when
the baseline data are collected. This face-to-face assist-
ance and support in ﬁlling the questionnaire will help
encourage patients and increase their conﬁdence in
completing questionnaires after discharge.
The patient has consented to be contacted by post or
by telephone for follow-up purposes. Prior to the
follow-up questionnaires being sent to patients at home,
their vital status will be conﬁrmed by a research team
member from study sites. The contact information and
patient status will be faxed from study sites to BCTU for
follow-up purposes. Follow-up questionnaire will include
pain questionnaires, patient satisfaction questionnaire
and assessment of single blinding. To be viable as a
primary outcome, we would expect to achieve a response
rate of 80% of expected patients, using various methods
of contact. We should be able to capture 100% of mor-
tality data via NHS tracing services. A withdrawal from
follow-up of over 10% would be disappointing. The
reasons for loss of follow-up if any will be documented
and reported at the end of the feasibility study.
Patient-reported outcomes
At baseline and prior to surgery, ﬁve sets of question-
naires will be completed. These comprise: Visual
Analogue Scale score, Brief Pain Inventory interference
score (BPI),29 30 Neuropathic Pain Scale (NPS),31
Generic health-related quality of life (EQ-5D-5L)32 and
Hospital Anxiety and Depression Scale (HADS).33
Inhospital data collection will include Visual Analogue
Scale scores, Brief Pain Inventory, analgesic use, any
acute complications conducted on day 1, day 2 and day
3 postsurgery. Using day of surgery as day 0, day 1 is
deﬁned as the ﬁrst full calendar day (from 12 midnight)
postsurgery, day 2 is the second full calendar day and
day 3 is the third full calendar day.
On hospital discharge, take home analgesia (TTOs),
inhospital mortality, acute complications, unplanned
admission to level 2 or level 3 care, including organ
support and length of level 2/level 3 stay and total
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length of hospital stay. Assessment and identiﬁcation
will be made for loss of data during inhospital stay to
improve data collection process for the substantive
trial.
Six sets of questionnaires will be completed prior on
hospital discharge and at 3 and 6 months postrandomi-
sation. The national registry will be checked to conﬁrm
patients status prior to follow-up questionnaires being
sent at 3 and 6 months. These questionnaires are Patient
satisfaction questionnaire with their overall care and
with their pain relief and question to assess whether
patient was aware of treatment allocation, Visual
Analogue scale scores, BPI,29 30 NPS,31 Generic
health-related quality of life (EQ-5D-5L)32 and HADS.33
Acceptability to and impact on patients
Patient interviews will explore the acceptability of the
intervention to patients and any impacts on their stay in
hospital and postdischarge. Semistructured qualitative
interviews will be undertaken with up to 30 study
patients with representation of patients taking part
across the 2 sites. The interviews will be conducted at
6–8 weeks postdischarge. This will allow for a reasonable
recovery period postsurgery and will enable interviews to
be undertaken with the small proportion of patients
who go on to need chemotherapy, prior to this treat-
ment beginning. The interviews will be performed by
telephone in order to minimise the disruption to and
effort required by patients.
All patients will be eligible for interview and will be
selected using maximum variety sampling by age, sex
and ethnic group.34 The need for a maximum variety
sample will be balanced against spacing the interviews as
evenly as possible across the 12 months of the trial so
that any variations in how the trial is implemented are
reﬂected in the patient sample. Interviews will be con-
ducted until saturation is achieved, which is likely to be
around 30 patients.35
A framework for the patient interviews will be devel-
oped in months 1–3 of the trial set-up period, with refer-
ence to the literature on similar trials. The framework
will also be discussed with Clinical Research Ambassador
Group (CRAG) based within HEFT. It will include ﬁve
core questions that will be asked of all patients, which
will cover:
▸ Reasons for taking part in the trial
▸ Assessing whether patients knew which anaesthetic
strategy they received
▸ The effectiveness of staff and written communication
about the trial
▸ How the trial impacted on their stay in hospital and
at home following discharge
▸ Suggestions for making improvements to the recruit-
ment processes
The semistructured nature of the interviews will allow
patients to raise issues which may not have been antici-
pated by the research team, and will allow the inter-
viewer to explore any patient concerns in depth. The
interviews are expected to last an average of 15–20 min,
and will be recorded digitally. If during the interviews,
any patients indicate that they have unresolved concerns
or clinical symptoms, they will be directed to their
named research nurse. Similarly, if patients get upset,
the interviewer will ask for the patient’s consent to be
contacted by their dedicated research nurse for further
discussion.
Telephone interviews will also be undertaken with up
to 10 patients who declined to take part in the trial, to
explore their reasons for declining and to identify how a
larger trial could be adapted to encourage higher rates
of participation.
Assessment of trial processes and impact on staff
Semistructured qualitative interviews with clinical and
research staff will be undertaken to explore the effective-
ness and efﬁciency of the trial processes. This will
include exploring a number of the secondary outcomes:
▸ The effectiveness of the patient identiﬁcation and
screening processes
▸ Identiﬁcation of reasons for failure to recruit patients
▸ The willingness of surgeons and anaesthetists to take
part
▸ The effectiveness of the randomisation process
Interviews will also ask for staff ideas for improvement
in trial processes, and explore whether there are any
unintended consequences of the trial procedure which
might have an impact on patient care processes or the
organisation and management of care.
Up to 20 staff interviews will be undertaken, which will
be spread evenly across the two sites and will include the
main clinical and managerial roles affected by the trail.
The interviews will be undertaken in the month follow-
ing the discharge of the last trial patient home. The
interviews are expected to last an average of 20–30 min,
and will be recorded digitally Data Collection and
Management.
All data for an individual patient will be collected by
each Principal Investigator or their delegated nominees
and recorded in the study-speciﬁc data collection forms
(CRF). Participants will only be identiﬁed through their
unique trial number allocated at the time of randomisa-
tion and their initials. Data will be collected from the
time the patient is entered into the trial through their
discharge from hospital and up to 6 months postsurgery.
STATISTICS AND DATA ANALYSIS
Sample size calculation
We expect to recruit between 50 and 75 patients
depending on the number we ﬁnd eligible for the study.
For example, we estimate that there will be ∼500 open
elective thoracotomies over 12 months from the 2 sites
(HEFT and UHSM), of which 60% will be eligible (300).
Using our own target criteria of 25% recruited would
make 75 participants. This number will allow us to
measure the recruitment rate with 95% CI of width
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∼10%. It will also be enough to estimate the SD of VAS
score with 95% CI of width 7 points (assuming the SD is
around 25 points).
Data analysis
The size of this study will not allow reliable assessment
of the effect of the intervention on outcomes and so
hypothesis testing is not proposed. Analyses of feasibility
and patient-reported outcomes will primarily take the
form of simple descriptive statistics (eg, proportions and
IQRs, means and SDs) and where appropriate, point
estimates of effects sizes (eg, mean differences and rela-
tive risks) and associated 95% CIs.
In the ﬁrst instance, for patient-reported outcomes,
participants will be kept in the groups they were allo-
cated, regardless of compliance with treatment
(intention-to-treat). Analysis will be completed once all
patients have completed 6-month follow-up. A Statistical
Analysis Plan will be generated for review by the Trial
Oversight Committee before any analysis takes place.
Handling missing data
There is a potential for some missing data to occur at
follow-up; however, a member of the research team will
contact patients for any missing data (eg, questionnaire)
via telephone and post. Where patients attend for
follow-up clinic, the potential for missing data will again
be limited, and the secondary outcome data will also be
collected at this point. Imputation of missing responses
is not proposed for patient-reported outcome as this is
not a deﬁnitive trial and no hypothesis testing will be
performed
Data management and quality assurance
Data management and confidentiality
Personal data and sensitive information required for the
TOPIC feasibility study will be collected directly from
trial participants and hospital notes on data collection
forms, coded with the participant’s unique trial number
and initials. All other patient identiﬁable information
will be removed. Participants will be asked for their
consent to transfer this information, including their
name and contact address for follow-up to the BCTU
ofﬁce based in University of Birmingham. The data col-
lected will be entered onto a secure computer database
by BCTU staff. This database, once completed, will be
locked under the direction of LM (Senior Statistician)
for analysis.
All personal information received in paper format for
the trial will be held securely and treated as strictly conﬁ-
dential according to NHS policies. All staff involved in
the study (clinical, academic, BCTU) share the same
duty of care to prevent unauthorised disclosure of per-
sonal information. No data that could be used to iden-
tify an individual will be published. Data will be stored
on a secure server at BCTU under the provisions of the
Data Protection Act and/or applicable laws and regula-
tions. The trial coordinator, study statistician and the
data manager will have access to the database until com-
pletion of the analysis. Data may be accessed by external
regulatory agencies and the Study Sponsor representa-
tives and permission for this access will be documented
within the participants consent form.
Data quality assurance and validation
The study will adopt a centralised approach to monitor-
ing data quality and compliance. A computer database
will be constructed speciﬁcally for the study data and
will include range and logic checks to prevent erroneous
data entry. Independent checking of data entry of paper
questionnaires will be periodically undertaken on small
subsamples. The trial statistician (LM) will regularly
check the balance of allocations by the stratiﬁcation vari-
ables. Source data veriﬁcation will only be employed if
there is reason to believe data quality has been compro-
mised, and then only in a subset of practices.
Quality assurance will begin with a clearly documented
staff training programme. A register of staff who have
been trained, and their competence assessed will be
maintained, and only staff whose names appear on this
list will be permitted to undertake study procedures.
Staff will also receive regular update training and peri-
odic reassessment of their competence. Real-time
reports will be available to staff indicating missing test
and questionnaire data for all participants at that centre.
This will be supplemented by regular reminders from
the TOPIC Trial Ofﬁce for incomplete data.
Monitoring and audit
The study will be monitored and/or audited by HEFT
under their remit as Sponsor and other regulatory
bodies to ensure adherence to Good Clinical Practice
and the NHS Research Governance Framework for
Health and Social Care (2nd edition).
Monitoring of study data shall include conﬁrmation of
informed consent; source data veriﬁcation; data storage
and data transfer procedures; local quality control
checks and procedures, back-up and disaster recovery of
any local databases and validation of data manipulation.
The trial coordinator, or where required, a nominated
designee of the Sponsor, shall carry out monitoring of
study data as an ongoing activity.
The ﬁrst study participant who has been randomised,
received surgery and completed up to the 72 hour
follow-up stage of the protocol will be monitored by the
Sponsors QA Manager to ensure the protocol is ﬁt for
purpose and review protocol adherence. Monitoring of
study participants by the Sponsors QA manager will
then occur at random intervals throughout the study
based on recruitment.
Study conduct will be subject to systems audit of the
Study Record for inclusion of essential documents; per-
missions to conduct the trial; Study Delegation Log; CVs
of study staff and training received; local document
control procedures; consent procedures and recruitment
logs; adherence to procedures deﬁned in the protocol
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(eg, inclusion/exclusion criteria, timeliness of visits);
accountability of study materials and equipment calibra-
tion logs. This will be led by the trial coordinator and
reported back to the Sponsor and the Sponsorship
Oversight Committee.
Entries on CRFs will be veriﬁed by inspection against
the source data. A sample of CRFs (10%) will be checked
on a regular basis for veriﬁcation of all entries made. In
addition, the subsequent capture of the data on the study
database will be checked. Where corrections are required,
these will carry a full audit trail and justiﬁcation.
Study data and evidence of monitoring and systems
audits will be made available for inspection by the regu-
latory authority as required.
Long-term storage of data
Trial data will be stored archived after the formal closure
of the trial in accordance with archive policy and for the
appropriate duration as per current legislation.
The computer database may be stored within the
BCTU and will be processed according to their trial
archiving policies.
SPONSORSHIP AND INDEMNITY
HEFTwill act as the Sponsor to this study. Delegated respon-
sibilities will be assigned to the Chief Investigator and the
NHS Trust(s) taking part in this study. The non-commercial
model clinical trials agreement will be used with all partici-
pating sites detailing their local responsibilities.
HEFT holds standard NHS Hospital indemnity and
insurance cover with NHS Litigation Authority for NHS
Trusts in England, which apply to this study.
REGULATORY APPROVALS
The study has obtained ethical approval from NHS
Research Ethics Committee (REC number 14/EM/
1280).
STUDY DISSEMINATION
This feasibility study is designed to identify if a substan-
tive trial is possible. Although a deﬁnitive answer to the
key research question on effectiveness of PVB on CPTP
cannot be provided, the ﬁndings of this feasibility study
will be of scientiﬁc interest to others in their own right.
The feasibility study will be registered on clinical trials
database (http://www.clinicaltrials.gov). We plan the dis-
semination strategy in three aspects. The ﬁrst will ensure
that patients and health professionals are informed of
the feasibility ﬁndings; the second will engage multidis-
ciplinary professionals to support a proposal of a deﬁni-
tive RCT and the third will be to resubmit for a full HTA
application dependant on the success of the feasibility
study.
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